Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.62 |
| ▸ | GHSR | Q92847 | 3/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711458 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL1711230 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL1711453 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL31254405 | 1.00 | GNPAT (0.62) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL30579779 | 0.99 | GNPAT (0.61) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL16970314 | 0.95 | GNPAT (0.60) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL16970311 | 0.95 | GNPAT (0.60) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL31181219 | 0.95 | GNPAT (0.57) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL30497010 | 0.95 | GNPAT (0.57) | GNPATGHSRERAP2LNPEPCPB2 | |
| SCHEMBL29531757 | 0.95 | GHSR (0.56) | GNPATGHSRERAP2LNPEPCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427051-A | Therapeutic agents and conjugates thereof | 北京轩义医药科技有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | claimed |
| US-20220257516-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-08-18 | — | — | US | claimed |
| EP-3996750-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Oregon Health & Science University (US) | 2022-05-18 | — | — | EP | claimed |
| CN-112604004-B | Anti-human EGFR antibody drug conjugate and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-05-10 | — | — | CN | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | claimed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | claimed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | claimed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | claimed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | claimed |
| EP-2173739-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2010-04-14 | — | — | EP | claimed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | claimed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | claimed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | claimed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | GNPAT 1927/4885GHSR 2481/4885ERAP2 3834/4885 |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | GNPAT 1411/4885GHSR 2509/4885ERAP2 4123/4885 |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | GNPAT 1693/4885GHSR 1155/4885ERAP2 46/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | GNPAT 1698/4885GHSR 1972/4885ERAP2 2981/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | GNPAT 1411/4885GHSR 2509/4885ERAP2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.